Information Provided By: 
Fly News Breaks for June 21, 2016
IPXL
Jun 21, 2016 | 12:23 EDT
JPMorgan analyst Dana Flanders said he views Impax Laboratories' (IPXL) deal to acquire a portfolio of generic products from Teva (TEVA) and Allergan (AGN) as an "attractive" one that includes high-margin, limited competition products, but also said it is "disappointing" that the company's updated guidance implies a cut to its prior standalone view. Flanders sees long-term opportunities for Impax, but limited near-term catalysts, leaving him with a Neutral rating on the stock.
News For IPXL From the Last 2 Days
There are no results for your query IPXL
